Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data

• Published in: Pathology oncology research 2023-04, Vol.29, p.1611077-1611077
• Main Authors: Revesz, Janos, Posfai, Boglarka, Pajor, Laszlo, Papdan, Timea, Varga, Linda, Paczona, Viktor R, Varga, Zoltan, Sukosd, Farkas, Maraz, Aniko
• Format: Article
• Language: English
• Subjects: B7-H1 Antigen - metabolism; combined positive score; FGFR mutation; fibroblast growth factor receptor; Humans; Mutation; Pathology and Oncology Archive; programmed death-ligand 1 expression; Retrospective Studies; urinary bladder cancer; Urinary Bladder Neoplasms - pathology
• ISSN: 1532-2807; 1219-4956; 1532-2807
• DOI: 10.3389/pore.2023.1611077

Programmed cell death (PD)-1/PD-ligand 1 (PD-L1) inhibitors have made a breakthrough in the therapy of advanced urothelial bladder cancer (UBC). The impact of Fibroblast Growth Factor Receptor 3 (FGFR3) mutation on the effectiveness of PD-L1 treatment remains still unclear. Objective: Our study aimed to investigate the frequency of FGFR mutations at different tumor stages, and their relation to PD-L1 status and survival. 310 patients with urothelial bladder cancer and subsequent radical cystectomy were included in a retrospective study over a 10-year study period at the University of Szeged, Hungary. FGFR3 mutations from the most infiltrative areas of the tumor were analyzed by targeted next-generation sequencing and PD-L1 (28-8 DAKO) tests (tumor positive score -TPS and combined positives score-CPS). In T0 cases FGFR3 mutations were analyzed from the earlier resection samples. Survival and oncological treatment data were collected from the National Health Insurance Fund (NHIF). Neoadjuvant, adjuvant and palliative conventional chemotherapies were allowed; immunotherapies were not. The relationship between the covariates was tested using chi-square tests, and survival analysis was performed using the Kaplan-Meier model and Cox proportional hazards regression. PD-L1 and FGFR could be tested successfully in 215 of the 310 UBC samples [pT0 19 (8.8%); St.0-I 43 (20%); St.II 41 (19%); St.III-IV 112 (52%)]. Significant pairwise dependency was found between tumor stage, FGFR3 mutation status and PD-L1 expression ( < 0.01). Samples with FGFR mutation were more common in less advanced stages and were also less likely to demonstrate PD-L1 expression. The effect of all investigated factors on survival was found to correlate with tumor stage. FGFR alteration frequency varied between the different stages of cancer. Higher positivity rates were observed at early stages, but lower levels of PD-L1 expression were detected in patients with FGFR mutations across at all stages of the disease.